Clinical Trial Detail

NCT ID NCT04061980
Title Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors OHSU Knight Cancer Institute
Indications

thyroid gland cancer

Therapies

Binimetinib + Encorafenib

Binimetinib + Encorafenib + Nivolumab

Age Groups: adult senior

Additional content available in CKB BOOST